Two Sinopharm Shots That Target Omicron to Start Hong Kong Trials

A healthcare worker prepares a dose of Sinovac Biotech Ltd. Covid-19 vaccine at a community vaccination center in Hong Kong, China, on Sunday, Feb. 27, 2022. The city is battling to contain an outbreak of the omicron variant of the virus that has strained its healthcare system, and raised questions about its Covid Zero strategy. Photographer: Justin Chin/Bloomberg

(Bloomberg) -- A China National Pharmaceutical Group Co. unit said it’s received approval to start clinical trials in Hong Kong of two inactivated vaccines that target the omicron variant of coronavirus.

China National Biotec Group Company Ltd., a vaccine-developing subsidiary of the state-owned pharmaceutical giant known as Sinopharm, announced the news on its WeChat account on Saturday. The trials will look at the safety of the inoculations and their ability to stimulate an immune response in adults who have received two or three doses.

You've accessed an article available only to subscribers

Subscribe today for just $.99.

VIEW OPTIONS

Share this article

Open WeChat and scan the QR code

GALLERY

: Gallery: Russian Troops Seize Key Ukrainian Stronghold

PODCAST

Caixin China Biz Roundup: Crypto Bet Turns Ugly for Beauty App

MOST POPULAR

1: In Depth: How Chinese Factories Are Finding Their Way to Mexico

2: Four Things to Know About Chinese Policy Banks’ Extra $120 Billion for Infrastructure

3: In Depth: How SoftBank Wrestled Back Control of Arm China

4: Chinese Tech Giants Cut Back on Office Space in Shenzhen

5: Boeing Pain From U.S.-China Trade War Seen in Airbus Buying Bonanza